Biopharmaceutical Merger and Presentations

LENZ Therapeutics and Graphite Bio announce a merger agreement to create a late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics lead assets for the treatment of presbyopia. Opthea, a biopharmaceutical company, will present at the Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference and appoints Frederic Guerard as CEO and Peter Lang as CFO. Opthea will also participate at the 2023 Euretina Congress and feature its first-in-class VEGF-C/D trap inhibitor, OPT-302, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting.